Metronidazole is a nitroimidazole antibiotic with a uniquely selective mechanism: it requires reductive activation that occurs only in anaerobic or microaerophilic organisms, which is why it is bactericidal for anaerobes and protozoal pathogens but inactive against aerobic bacteria. This selectivity, combined with excellent pharmacokinetics (PK) including outstanding central nervous system (CNS) penetration, makes it indispensable in the treatment of anaerobic and protozoal infections.1
Metronidazole enters bacterial and protozoal cells by passive diffusion. Within anaerobic organisms, the nitro group of the drug is reduced by ferredoxin-linked electron transport proteins, generating short-lived cytotoxic nitroso free radicals and other reactive intermediates.1 These intermediates interact with deoxyribonucleic acid (DNA), causing strand breakage, helix destabilization, and loss of the helical structure required for replication and transcription, ultimately producing rapid bactericidal or protozoal killing. The selectivity of this mechanism is absolute: reduction of the nitro group requires the low intracellular redox potential characteristic of anaerobic metabolism. Aerobic bacteria maintain a redox environment that does not reduce the nitro group, so metronidazole remains in its inactive prodrug form and exerts no antibacterial effect in these organisms. This makes metronidazole one of the few antibiotics whose mechanism of action is genuinely selective based on the metabolic state of the target organism rather than a structural difference in a target enzyme.
The antibacterial and antiprotozoal spectrum of metronidazole covers obligate anaerobes and certain microaerophilic and protozoal pathogens. Among bacteria, it is reliably active against virtually all clinically important Gram-negative anaerobes including Bacteroides fragilis and the broader Bacteroides group, Fusobacterium species, and Prevotella species, as well as Gram-positive anaerobes including Clostridium difficile (C. diff), Clostridium perfringens, and Peptostreptococcus species.2 Activity is less reliable against some Gram-positive anaerobes such as Propionibacterium acnes and Actinomyces. Among protozoal pathogens, metronidazole is the drug of choice for Trichomonas vaginalis (trichomoniasis), Giardia lamblia (giardiasis), and Entamoeba histolytica (amebiasis). It has no activity against aerobic or facultatively anaerobic bacteria, fungi, or viruses.
Metronidazole has highly favorable PK for a drug that treats anaerobic and deep-tissue infections. Oral bioavailability is approximately 80 to 100 percent, making oral and intravenous (IV) formulations essentially interchangeable in patients with functioning gastrointestinal (GI) tracts and no concern about oral absorption.3 The volume of distribution (Vd) is approximately 0.6 to 1.0 L/kg, reflecting extensive tissue penetration into most body compartments. Protein binding is low at approximately 10 to 20 percent, contributing to wide tissue distribution. Elimination is primarily hepatic through oxidation and glucuronide conjugation, with a half-life of approximately 6 to 10 hours permitting twice-daily or three-times-daily dosing. Renal excretion accounts for approximately 60 to 80 percent of elimination as metabolites; dose adjustment is not required for renal impairment, but in severe hepatic impairment the half-life is prolonged and dose reduction is warranted.
The CNS penetration of metronidazole is exceptional among antibiotics and is clinically relevant for several conditions. It crosses the blood-brain barrier freely, achieving cerebrospinal fluid (CSF) concentrations of approximately 43 to 100 percent of simultaneous plasma levels even without meningeal inflammation, making it one of the few oral agents capable of achieving therapeutic CNS concentrations for susceptible anaerobes.3 This property underlies its use in brain abscess, where anaerobes are frequent contributors to the polymicrobial flora, as well as in CNS infections due to susceptible organisms. Metronidazole achieves adequate concentrations in virtually all other tissues including bile, saliva, vaginal secretions, and bone, supporting its use across the full anatomical range of anaerobic infections.
Metronidazole oral bioavailability of 80 to 100 percent means that a patient who can swallow and absorb should receive the oral formulation rather than IV. There is no pharmacokinetic rationale for maintaining IV metronidazole in a patient tolerating oral medications, and converting to oral therapy is both safe and cost-effective. IV metronidazole is appropriate for nil-per-os patients, those with significant GI malabsorption, or those requiring rapid loading in severe infections.
Metronidazole's adverse effect profile is generally manageable for short courses but includes several clinically important interactions and dose-dependent toxicities that limit use in certain settings. Its clinical applications span intra-abdominal infections, C. diff, bacterial vaginosis (BV), pelvic inflammatory disease (PID), and protozoal infections.4
The most widely recognized adverse effect of metronidazole is the disulfiram-like reaction with ethanol consumption. Metronidazole inhibits aldehyde dehydrogenase, the enzyme responsible for oxidizing acetaldehyde to acetate in ethanol metabolism, causing acetaldehyde accumulation.4 The resulting reaction includes flushing, palpitations, nausea, vomiting, headache, and in severe cases hypotension and cardiovascular collapse. Patients must be counseled to avoid all alcohol-containing beverages, foods cooked with wine or spirits, and alcohol-containing medications (including some mouthwashes and liquid preparations) during therapy and for at least 48 hours after completing a course, due to the persistence of the drug and its active metabolites. This counseling must be explicit and specific; patients frequently fail to connect their reaction to alcohol-containing sources they have not considered.
Neurological adverse effects are the most serious toxicities associated with metronidazole, particularly with prolonged use or high cumulative doses. Peripheral neuropathy is the most common neurological complication, manifesting as distal sensory or sensorimotor neuropathy with numbness, tingling, and burning, particularly in the feet.5 The mechanism involves mitochondrial toxicity in peripheral neurons. Peripheral neuropathy may be partially reversible after drug discontinuation but can be permanent with prolonged exposure. Central nervous system (CNS) toxicity from metronidazole, while less common, can include cerebellar dysfunction (ataxia, dysarthria, nystagmus), encephalopathy, and seizures. Metronidazole-induced encephalopathy produces a characteristic pattern on magnetic resonance imaging (MRI) with symmetric T2 (T2-weighted sequence)-hyperintense lesions in the dentate nuclei and dorsal brainstem. This MRI pattern is reversible if metronidazole is promptly discontinued. Given these neurological risks, courses exceeding four weeks should be avoided where possible and the cumulative dose monitored.
Metronidazole inhibits the cytochrome P450 (CYP) isoform CYP2C9 (cytochrome P450 2C9), which is responsible for metabolizing the S-enantiomer of warfarin (the more pharmacologically active isomer), resulting in clinically significant potentiation of the anticoagulant effect.4 Patients receiving warfarin who are prescribed metronidazole require close international normalized ratio (INR) monitoring, typically within one week of initiation, and warfarin dose reduction is frequently necessary. Metronidazole also interacts with lithium, reducing renal lithium clearance and increasing the risk of lithium toxicity; lithium levels should be monitored when the combination is used. Common gastrointestinal (GI) adverse effects include nausea, a metallic or bitter taste in the mouth, and anorexia, which collectively contribute to nonadherence particularly in courses longer than one week.
Clinically, metronidazole is a cornerstone of anaerobic infection management. For intra-abdominal infections including complicated appendicitis, diverticulitis, and secondary peritonitis, it is combined with agents covering Gram-negative aerobes (typically a fluoroquinolone, aminoglycoside, or third-generation cephalosporin) to provide comprehensive anaerobic and aerobic coverage.2 For brain abscess of odontogenic or sinogenic origin, where Streptococcus species and anaerobes predominate, metronidazole combined with a third-generation cephalosporin remains a standard regimen given its excellent CNS penetration. For C. diff infection, oral vancomycin and fidaxomicin are now preferred over metronidazole for all severity categories per current guidelines, with oral metronidazole relegated to situations where neither preferred agent is available.15 For bacterial vaginosis, metronidazole (either 500 mg oral twice daily for seven days or 0.75 percent vaginal gel) remains a first-line treatment.14
Resistance to metronidazole is an increasing clinical concern, particularly in Helicobacter pylori and Trichomonas vaginalis. The primary resistance mechanism in anaerobic bacteria involves reduced expression or mutation of the nitroreductase enzymes (ferredoxin and pyruvate-ferredoxin oxidoreductase) responsible for activating the drug, or upregulation of deoxyribonucleic acid (DNA) repair mechanisms that counteract the drug-induced strand breaks.1 In H. pylori, metronidazole resistance rates exceed 20 to 40 percent in many populations, making susceptibility testing or alternative regimen selection important when metronidazole-containing triple therapy is being considered. In T. vaginalis, resistance is increasingly encountered and may require high-dose metronidazole or substitution with tinidazole, a related nitroimidazole with greater bioavailability and a longer half-life that is sometimes effective against metronidazole-resistant isolates.
Current Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) guidelines recommend oral vancomycin (125 mg four times daily) or fidaxomicin (200 mg twice daily) for all initial episodes of C. diff infection, including non-severe cases. Oral metronidazole is acceptable only when access to preferred agents is unavailable. It should not be used for severe or complicated C. diff infection under any circumstances.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding the 50S ribosomal subunit at a site overlapping with that of macrolides and chloramphenicol. Its clinical value lies in two distinct domains: anaerobic infections where it provides excellent tissue penetration, and community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) skin and soft tissue infections where it often remains susceptible and can be used orally.6
Clindamycin binds to the 23S ribosomal RNA (rRNA) component of the 50S subunit at the peptidyl transferase center, inhibiting transpeptidation and translocation, and causing premature peptide chain termination.6 This binding site overlaps significantly with those of macrolides and chloramphenicol, which has important cross-resistance implications. The drug is bacteriostatic at most clinical concentrations, though it may be bactericidal at higher concentrations against some susceptible organisms. Beyond its antibacterial mechanism, clindamycin inhibits bacterial toxin production at sub-inhibitory concentrations by interfering with ribosomal translation of toxin genes, a property that is clinically exploited in severe toxin-mediated infections such as necrotizing fasciitis due to Streptococcus pyogenes (group A streptococcus, or GAS) and toxic shock syndrome, where clindamycin is added specifically to suppress toxin synthesis even when the organism is being killed by a beta-lactam.
The antibacterial spectrum of clindamycin encompasses most aerobic Gram-positive cocci and a broad range of anaerobes, but has no activity against Gram-negative aerobic organisms (whose outer membranes limit penetration) and variable activity against Gram-positive anaerobes. It is reliably active against methicillin-susceptible S. aureus (MSSA) and many CA-MRSA strains, Streptococcus pyogenes, Streptococcus agalactiae, and viridans streptococci.7 For anaerobes, clindamycin covers most Gram-positive anaerobes including Clostridium species (excluding C. diff, which is intrinsically resistant) and Peptostreptococcus species, as well as many Gram-negative anaerobes including Bacteroides fragilis, though resistance rates in B. fragilis have been increasing and now exceed 20 to 30 percent in many regions, limiting clindamycin's reliability as empiric monotherapy for serious intra-abdominal infections. Clindamycin has no activity against aerobic Gram-negative bacteria, atypical organisms, or enterococci.
Clindamycin pharmacokinetics are well suited to outpatient oral therapy. Oral bioavailability is approximately 90 percent and is not significantly affected by food, allowing flexible dosing schedules.6 The volume of distribution (Vd) is large (approximately 0.6 to 1.2 L/kg) with excellent penetration into bone, joints, lung, and soft tissue. It concentrates in abscesses and achieves clinically relevant concentrations within phagocytes. Central nervous system (CNS) penetration is poor and clindamycin is not appropriate for CNS infections. Protein binding is high at approximately 93 percent. Elimination is primarily hepatic via CYP3A4 (cytochrome P450 isoform 3A4)-mediated metabolism with biliary excretion; no dose adjustment is required for renal impairment, but reduction is warranted in severe hepatic impairment. The half-life is approximately 2 to 3 hours, supporting dosing every 6 to 8 hours.
The most feared adverse effect of clindamycin is Clostridioides difficile infection. Clindamycin is among the antibiotics most strongly associated with C. diff colitis, along with fluoroquinolones and broad-spectrum beta-lactams, due to its profound disruption of the normal colonic anaerobic flora that provides colonization resistance against C. diff.8 Any patient who develops diarrhea during or after clindamycin therapy must be evaluated for C. diff, even weeks after the course has been completed. This risk is not eliminated by topical or vaginal formulations, which achieve measurable systemic absorption. Additional adverse effects include gastrointestinal (GI) upset (nausea, diarrhea, abdominal cramping), hepatotoxicity with elevated transaminases (usually reversible), and rare cases of drug-induced esophagitis if capsules are swallowed without adequate water. Neuromuscular blockade has been reported at very high doses, particularly in combination with neuromuscular blocking agents used in anesthesia.
The macrolide-lincosamide-streptogramin B (MLSB) resistance phenotype is the primary resistance mechanism relevant to clindamycin. The constitutive MLSB phenotype, mediated by erm genes encoding methyltransferases that methylate the 23S rRNA binding site, confers high-level resistance to all three drug classes simultaneously (macrolides, lincosamides including clindamycin, and streptogramin B).9 The inducible MLSB phenotype presents a critical diagnostic challenge: organisms carrying an inducible erm gene appear clindamycin-susceptible on routine disk diffusion because only the macrolide-containing disk induces expression. However, when clindamycin therapy is used, the drug can itself induce erm expression in vivo, leading to treatment failure. The D-zone test (double-disk diffusion) detects inducible resistance: a blunted zone of inhibition (D-shaped) around the clindamycin disk in proximity to an erythromycin disk indicates inducible resistance, and clindamycin should be avoided despite apparent in vitro susceptibility.
An MRSA isolate reported as clindamycin-susceptible and erythromycin-resistant should prompt D-zone testing before prescribing clindamycin. If the D-zone test is positive (D-shaped inhibition zone), the isolate has inducible MLSB resistance and clindamycin will select for resistant mutants during therapy, causing treatment failure. Always request D-zone testing or confirm the susceptibility report explicitly states the inducible resistance screen was performed and is negative before relying on clindamycin for MRSA.
This section covers four additional antibacterial classes with distinct mechanisms and highly specific clinical niches. Fosfomycin and nitrofurantoin are oral agents largely restricted to urinary tract infection (UTI). Trimethoprim-sulfamethoxazole (TMP-SMX) has broad applications from UTI to Pneumocystis prophylaxis to methicillin-resistant Staphylococcus aureus (MRSA) skin infections. Polymyxins (colistin and polymyxin B) are last-resort agents for carbapenem-resistant Gram-negative infections, with a narrow therapeutic window.10
Fosfomycin inhibits the enzyme MurA (uridine diphosphate-N-acetylglucosamine [UDP-N-acetylglucosamine] enolpyruvyl transferase), which catalyzes the first committed step in peptidoglycan biosynthesis, specifically the transfer of the enolpyruvyl moiety to N-acetylglucosamine.10 This mechanism is entirely distinct from beta-lactam, glycopeptide, and all other cell wall agents, such that fosfomycin retains activity against many organisms resistant to other cell wall-active drugs. In the United States, fosfomycin is available as a single 3 g oral sachet for uncomplicated lower UTI, particularly due to Escherichia coli and Enterococcus faecalis including extended-spectrum beta-lactamase (ESBL)-producing strains. It achieves extremely high urinary concentrations (several hundred times the minimum inhibitory concentration (MIC) for susceptible organisms) but inadequate systemic and tissue concentrations for infections outside the urinary tract. The single-dose regimen for uncomplicated cystitis achieves clinical cure rates comparable to three-day fluoroquinolone regimens and is highly favored from a stewardship perspective.14
Nitrofurantoin is reduced within bacterial cells by a flavoprotein nitroreductase to multiple reactive intermediates that simultaneously damage multiple bacterial targets including deoxyribonucleic acid (DNA), ribonucleic acid (RNA), ribosomes, and cell wall proteins, producing broad intracellular disruption.11 This multi-target mechanism is why resistance, though it exists, is uncommon. Nitrofurantoin achieves adequate antibacterial concentrations only in urine and is therefore appropriate exclusively for lower UTI; it must never be used for pyelonephritis (renal parenchymal infection) because it does not achieve bactericidal concentrations in renal tissue or bloodstream. The macrocrystalline formulation is better tolerated than the older microcrystalline form and is standard for the five-day regimen used for uncomplicated cystitis. Nitrofurantoin is not active against Proteus mirabilis, Pseudomonas aeruginosa, or Klebsiella pneumoniae in most cases, limiting it to cystitis caused by susceptible E. coli and Staphylococcus saprophyticus. It is contraindicated when creatinine clearance (CrCl) falls below 30 mL/min because inadequate urinary drug concentrations are achieved and pulmonary and hepatic toxicity risks increase. The most serious adverse effects are pulmonary toxicity (acute hypersensitivity pneumonitis or, with prolonged use, chronic interstitial fibrosis) and hepatotoxicity; both are rare with short courses but must be monitored with long-term prophylactic use.
Trimethoprim-sulfamethoxazole (TMP-SMX) produces sequential blockade of the bacterial folate synthesis pathway: sulfamethoxazole (SMX) competitively inhibits dihydropteroate synthase (DHPS), blocking incorporation of para-aminobenzoic acid (PABA) into dihydropteroic acid, while trimethoprim (TMP) inhibits dihydrofolate reductase (DHFR), blocking reduction of dihydrofolate to tetrahydrofolate.12 The two drugs act on sequential steps in the same pathway, producing synergistic inhibition that together prevent synthesis of tetrahydrofolate, the cofactor essential for purine and thymidine synthesis. The spectrum of TMP-SMX covers most community-acquired Gram-negative Enterobacteriaceae (when susceptible), Stenotrophomonas maltophilia (for which TMP-SMX is a primary treatment), community-acquired MRSA (CA-MRSA), Nocardia species, and Pneumocystis jirovecii, the causative agent of Pneumocystis pneumonia (PCP), for which TMP-SMX is used for both prophylaxis and treatment at high doses. Adverse effects include allergic reactions (sulfonamide hypersensitivity rash, which can progress to Stevens-Johnson syndrome in rare cases), hyperkalemia (TMP blocks renal tubular potassium secretion via its action on epithelial sodium channels), elevation of serum creatinine without true reduction in glomerular filtration rate (GFR), myelosuppression (particularly with high-dose therapy or in folate-deficient patients), and photosensitivity.
Polymyxins (colistin, also known as polymyxin E, and polymyxin B) are cyclic lipopeptide antibiotics that disrupt the outer and inner membranes of Gram-negative bacteria. They bind to lipopolysaccharide (LPS) in the outer membrane via electrostatic interaction between their positively charged cyclic peptide ring and the negatively charged phosphate groups of lipid A, displacing divalent cations (calcium and magnesium) that normally stabilize the outer membrane structure.13 This permeabilizes the outer membrane and disrupts the inner membrane, causing rapid leakage of cytoplasmic contents and cell death. Polymyxins are active exclusively against Gram-negative bacteria; their spectrum includes Pseudomonas aeruginosa, Acinetobacter baumannii, and most Enterobacteriaceae including carbapenem-resistant strains, making them among the very few options for carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE).
Colistin is administered IV as colistimethate sodium, an inactive prodrug converted to active colistin in vivo. Nephrotoxicity is the primary dose-limiting adverse effect, occurring in 30 to 60 percent of patients receiving IV colistin in some series; it is dose-dependent and often reversible, but can be severe.13 Neurotoxicity (facial paresthesias, dizziness, peripheral neuropathy) and, rarely, neuromuscular blockade also occur. Given the narrow therapeutic window and significant toxicity, polymyxins are reserved for infections caused by organisms with no other active therapeutic options, and combination therapy with other agents (meropenem, rifampicin, tigecycline) is often employed, though the evidence base for combination superiority over polymyxin monotherapy remains limited.
Fosfomycin (single dose) and nitrofurantoin (five days) are first-line options for uncomplicated cystitis in women when TMP-SMX local resistance rates exceed 20 percent or the patient has a sulfonamide allergy. TMP-SMX remains first-line where susceptibility is confirmed. Nitrofurantoin must never be used for pyelonephritis. Polymyxins are strictly reserved for documented carbapenem-resistant Gram-negative infections with no other active agents; they are not empiric drugs and must not be used for susceptible organisms due to nephrotoxicity and the risk of promoting resistance to this last-resort class.
Leitsch D. A review on metronidazole: an old warhorse in antimicrobial chemotherapy. Parasitology. 2019;146(9):1167–1178.
doi:10.1017/S0031182017002025Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133–164.
doi:10.1086/649554Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 1999;36(5):353–373.
doi:10.2165/00003088-199936050-00004O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med. 1976;295(7):354–357.
doi:10.1056/NEJM197608122950702Kuriyama A, Jackson JL, Doi A, Kamiya T. Metronidazole-induced central nervous system toxicity: a systematic review. Clin Neuropharmacol. 2011;34(6):241–247.
doi:10.1097/WNF.0b013e3182334b35Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10–e52.
doi:10.1093/cid/ciu296Falagas ME, Gorbach SL. Clindamycin and metronidazole. Med Clin North Am. 1995;79(4):845–867.
doi:10.1016/S0025-7125(16)30043-8Kelly CP, LaMont JT. Clostridium difficile — more difficult than ever. N Engl J Med. 2008;359(18):1932–1940.
doi:10.1056/NEJMra0707500Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002;34(4):482–492.
doi:10.1086/324626Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333–1341.
doi:10.1086/429323Cunha BA. Nitrofurantoin — current concepts. Urology. 1988;32(1):67–71.
doi:10.1016/0090-4295(88)90460-8Masters PA, O'Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med. 2003;163(4):402–410.
doi:10.1001/archinte.163.4.402Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53(9):879–884.
doi:10.1093/cid/cir611Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women. Clin Infect Dis. 2011;52(5):e103–e120.
doi:10.1093/cid/ciq257McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48.
doi:10.1093/cid/cix1085